Individual differences in efficacy and safety of drugs between patients are a significant problem in modern pharmacotherapy. The body’s pharmacological response to the administration of a particular drug is determined by multiple factors, where up to 50% of the variability of the pharmacological response may be determined by the genetic variability of the body. The article presents an up-to-date review of the data on genetic polymorphisms influencing the efficacy and safety of tamsulosin therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Keywords: CYP3A4, CYP2D6, LUTS, BPH, tamsulosin